Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Towards A Unified Model Of RAF Inhibitor Resistance.

D. Solit, N. Rosen
Published 2014 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in patients with BRAF-mutant melanoma. Analysis of tumor samples collected at the time of disease progression indicates that alterations within the extracellular signal-regulated kinase (ERK) pathway that result in reactivation of ERK signaling are present in most patients. Mutations in the phosphoinositide 3-kinase/AKT pathway that enhance the adaptive response to RAF inhibitors also contribute to RAF inhibitor resistance in a subset of patients.
This paper references
10.1158/1078-0432.CCR-13-0661
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
E. Romano (2013)
10.1038/onc.2011.250
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
F. Xing (2012)
10.1038/nature09626
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
10.1158/2159-8290.CD-13-0617
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
E. V. Van Allen (2014)
10.1158/2159-8290.CD-13-0631
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
N. Wagle (2014)
10.1038/nature09454
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
G. Bollag (2010)
10.1158/2159-8290.CD-12-0470
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
S. Whittaker (2013)
10.1126/scisignal.2001148
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
R. Corcoran (2010)
10.1038/nature10662
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
P. Poulikakos (2011)
10.1038/nature08902
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
10.1158/2159-8290.CD-13-0279
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.
H. Shi (2014)
10.1038/ncomms1727
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H. Shi (2012)
10.1038/nature04304
BRAF mutation predicts sensitivity to MEK inhibition
D. Solit (2006)
10.1158/2159-8290.CD-13-0642
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
H. Shi (2014)
10.1016/j.ccr.2012.10.009
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Piro Lito (2012)
10.1200/JCO.2010.33.2312
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
N. Wagle (2011)
10.1038/nature11814
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
M. D. Thakur (2013)
10.1056/NEJMoa1210093
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
K. Flaherty (2012)



This paper is referenced by
Systematic analysis of BRAFV 600 E melanomas reveals a role for JNK / c-Jun pathway in adaptive resistance to drug-induced apoptosis
M. Fallahi-Sichani (2015)
10.1074/jbc.M115.712885
Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma*
Bingying Zhou (2016)
Melanoma Therapeutic St rategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence Graphical
K. R. Singleton (2017)
10.1158/2159-8290.CD-17-0172
Anaphase-Promoting Complex Adaptor FZR1/CDH1 Blocks BRAF Signaling Both by Targeting BRAF for Proteolytic Degradation and by Disrupting BRAF Dimerization.
C. Zhang (2017)
Supplementary Issue: Breast Cancer Detection and Screening
Xin Jin (2015)
10.1158/0008-5472.CAN-15-3425
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.
T. Horn (2016)
10.4161/23723548.2014.970955
The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression
A. Shilo (2015)
10.1038/nrc4018
Directly targeting transcriptional dysregulation in cancer
T. Gonda (2015)
10.1016/j.celrep.2017.11.022
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
K. R. Singleton (2017)
10.3390/cancers7030868
Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
C. P. Prasad (2015)
10.1038/s41598-017-19073-4
Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression
Berline Murekatete (2017)
10.4137/BCBCR.S25460
Targeting Breast Cancer Metastasis
Xin Jin (2015)
10.21007/ETD.CGHS.2015.0341
Overcoming Acquired Resistance to BRAF Inhibitors by Novel Synergistic Drug Combination and Discovery of Novel Smac Mimetics as Selective Survivin Inhibitors
Jin He Wang (2015)
Can the Dual Inhibition of Extracellular Signal-Related Kinase (ERK) and Phosphoinositide-3 Kinase (PI3K) Increase Efficacy of Cisplatin in Endometrial and Ovarian Cancers?
H. G. Schoch (2016)
Chapter 8 Emerging Drug Combination Approaches in Melanoma Therapy
J. Wang (2018)
Anomalies moléculaires de la voie MAPK et cancer papillaire de la thyroïde : étude de deux phosphatases spécifiques de ERK, DUSP5 et DUSP6
C. Buffet (2014)
10.1038/ncomms9390
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Jia-Ren Lin (2015)
10.1021/ACSCHEMBIO.9B00191
Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
A. Gunderwala (2019)
RAS signaling and therapeutic resistance in melanoma
Bingying Zhou (2016)
10.1093/noajnl/vdaa024
Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
Roei D Mazor (2020)
10.1007/978-1-4614-7322-0_35-1
Principles of Targeted Therapy
Gideon Bollag (2018)
10.18632/oncotarget.6548
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
Devin G. Roller (2016)
10.1158/2159-8290.CD-16-0647
The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.
Lixin Wan (2017)
10.5772/59360
Emerging Drug Combination Approaches in Melanoma Therapy
J. Wang (2015)
10.15252/msb.20145877
Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis
M. Fallahi-Sichani (2015)
10.1016/j.celrep.2016.05.064
BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
K. Kemper (2016)
10.3389/fphar.2016.00312
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy
J. Belizário (2016)
10.1016/j.molcel.2020.05.031
Rational Cancer Treatment Combinations: An Urgent Clinical Need.
J. Boshuizen (2020)
10.1158/0008-5472.CAN-15-1248
Mapping the Pathways of Resistance to Targeted Therapies.
K. Wood (2015)
10.1186/s12943-017-0645-4
The landscape of BRAF transcript and protein variants in human cancer
Andrea Marranci (2017)
Braf V600e Kinase Domain Duplication Identified in Therapy-refractory Melanoma Patient-derived Xenografts Resource Braf V600e Kinase Domain Duplication Identified in Therapy-refractory Melanoma Patient-derived Xenografts
Kristel Kemper ()
Resource BRAFV 600 E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts Graphical
K. Kemper ()
See more
Semantic Scholar Logo Some data provided by SemanticScholar